JCJasmin Coulombe-Huntington

Jasmin Coulombe-Huntington

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jasmin Coulombe-Huntington has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CRISPR screen uncovers SLC26A2 as a modulator of tungsten toxicity in endochondral ossification

    by Rowa Bakadlag, Sheena Li, Cynthia Guilbert, Caroline Huard, Thierry Bertomeu, Jasmin Coulombe-Huntington, Brian P. Jackson, Michael P. Grant, Lama Iskandarani, Chiara Paganini, et al.

  • Open Access

    A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture

    by Jasmin Coulombe-Huntington, Thierry Bertomeu, Caroline Huard, Andrew Chatr-Aryamontri, Daniel J. St-Cyr, María Sánchez-Osuna, David Papadopoli, Karine Normandin, Mohammadjavad Paydar, Shannon McLaughlan, et al.

    To probe drug mechanism of action (MOA) and interrogate the genetic architecture of human cells, we carried out isogenic genome-wide CRISPR/Cas9 knockout screens against 310 diverse drugs, bioactive compounds, and stress conditions. Stringent statistical correction for gene knockout fitness defects yielded a large-scale matrix of >12,000 high confidence chemical-genetic interactions (CGIs). This dataset revealed many previously unappreciated off-target effects for well-characterized compounds and novel MOAs for uncharacterized compounds. The CGI matrix uncovered dense genetic modules that yielded new biological insights into phospholipidosis, mitotic regulation, metabolism, the DNA damage response, and mTOR signaling. The dataset allowed identification of multi-drug sensitization and resistance mechanisms, inference of gene function, elaboration of cross-process connectivity, evaluation of the cell type specificity of CGIs, prediction of chemical synergism, and extensive annotation of understudied genes. This resource provides a map of the genetic landscape in human cells and a framework to help guide drug discovery.


  • Open Access

    The scaffold protein PRR14L links the PP2A-TACC3 axis to mitotic fidelity and sensitivity to MPS1 inhibition

    by Albert Z. Liu, Akshay Narkar, Keming Li, Thierry Bertomeu, Blake A. Johnson, Jasmin Coulombe-Huntington, Yi Dong, Jin Zhu, Mike Tyers, Rong Li

    Aneuploidy is a hallmark of cancer and is a potential vulnerability that can be selectively targeted. To systematically identify genes that affect the incidence and fitness of aneuploid cells, we conducted a genome-wide CRISPR/Cas9 screen using NMS-P715, an inhibitor of the spindle assembly checkpoint (SAC) kinase MPS1/TTK. In this study, we identified a number of genes known to regulate aneuploidy and mitosis, and subsequently focused on PRR14L , a ubiquitously expressed gene previously implicated in chronic myelomonocytic leukemia (CMML). Proximity labeling of PRR14L using TurboID revealed several cell division proteins, including the PP2A-B56 phosphatase complex and the spindle assembly factor TACC3, as PRR14L-interacting proteins. Loss of PRR14L prolongs SAC-dependent mitotic arrest in response to microtubule depolymerization but, paradoxically, leads to catastrophic mitotic errors upon SAC abrogation by MPS1 inhibitors. A model derived from our findings provides a rationale for exploiting MPS1 inhibition as a potential vulnerability in cancers containing either PRR14L loss of function mutations or FGFR-TACC3 fusions. Significance Statement: Aneuploidy is a hallmark of cancer. Whether aneuploidy can be selectively targeted is not known. Utilizing a CRISPR/Cas9 screen, the authors found that loss of the gene PRR14L sensitizes cells to aneuploidy induction. Taking advantage of live cell imaging and proximity labeling, they linked PRR14L to TACC3 and mitosis. These findings suggest that spindle checkpoint inhibitors may have therapeutic potential in cancers with either loss-of-function PRR14L and/or gain of function TACC3 mutations.

  • Open Access

    FiGS-MoD: Feature-informed Gibbs Sampling Motif Discovery Algorithm for Mapping Human Signaling Networks

    by Yitao Sun, Yu Xia, Jasmin Coulombe-Huntington

    Motivation: Short linear motifs (SLiMs) are short sequence patterns that mediate transient protein-protein interactions, often within disordered regions of proteins. SLiMs play central roles in signaling, trafficking, and post-translational regulation, but their short length and low complexity make them difficult to identify both experimentally and computationally. Since the latest release of motif discovery tools like MEME Suite, the availability of protein-protein interaction data (e.g., BioGRID) has increased by more than fivefold, providing richer network contexts where SLiMs can be inferred from recurring patterns of interaction. Combined with recent advances in machine learning, this creates new opportunities for large-scale, high-resolution motif discovery. Results: We present FiGS-MoD, a F eature- i nformed G ibbs S ampling Mo tif D iscovery algorithm with two key innovations: (i) incorporating biased sampling informed by residue-level features, including Protein Language Model (PLM) embeddings, AlphaFold2-derived disorder and solvent accessibility, and evolutionary conservation, and (ii) replacing the traditional position-specific scoring matrix (PSSM) with a Hidden Markov model (HMM) to accommodate insertions and deletions. We applied our algorithm to 12,765 sub-networks from the human interactome and provided 221,840 human SLiM predictions and quality scores as a public resource, along with the tool itself. Our method outperformed MEME in terms of recovering known motifs from the Eukaryotic Linear Motif (ELM) database and phosphosites from PhosphoGRID. Through three case studies, we further highlight the biological relevance of our results and the generalizability of the method to diverse motif classes. Availability and Implementation: Source code and a predicted SLiM dataset using FiGS-MoD are freely available at https://github.com/Eric3939/FiGS-MoD

  • Open Access

    Genetic enhancers of partial PLK1 inhibition reveal hypersensitivity to kinetochore perturbations

    by Karine Normandin, Jasmin Coulombe-Huntington, Corinne St-Denis, Alexandre Bernard, Mohammed Bourouh, Thierry Bertomeu, Mike Tyers, Vincent Archambault

    Polo-like kinase 1 (PLK1) is a serine/threonine kinase required for mitosis and cytokinesis. As cancer cells are often hypersensitive to partial PLK1 inactivation, chemical inhibitors of PLK1 have been developed and tested in clinical trials. However, these small molecule inhibitors alone are not completely effective. PLK1 promotes numerous molecular and cellular events in the cell division cycle and it is unclear which of these events most crucially depend on PLK1 activity. We used a CRISPR-based genome-wide screening strategy to identify genes whose inactivation enhances cell proliferation defects upon partial chemical inhibition of PLK1. Genes identified encode proteins that are functionally linked to PLK1 in multiple ways, most notably factors that promote centromere and kinetochore function. Loss of the kinesin KIF18A or the outer kinetochore protein SKA1 in PLK1-compromised cells resulted in mitotic defects, activation of the spindle assembly checkpoint and nuclear reassembly defects. We also show that PLK1-dependent CENP-A loading at centromeres is extremely sensitive to partial PLK1 inhibition. Our results suggest that partial inhibition of PLK1 compromises the integrity and function of the centromere/kinetochore complex, rendering cells hypersensitive to different kinetochore perturbations. We propose that KIF18A is a promising target for combinatorial therapies with PLK1 inhibitors.


  • Open Access

    Active growth signalling promotes cancer cell sensitivity to the CDK7 inhibitor ICEC0942

    by Gemma Wilson, Georgina Sava, Karla Vuina, Caroline Huard, Leticia Meneguello, Jasmin Coulombe-Huntington, Thierry Bertomeu, R.J. Maizels, Josh Lauring, Mike Tyers, et al.

    CDK7 has a central role in promoting cellular proliferation, through the activation of the mitotic CDKs, and by driving global gene expression, through targeting RNA polymerase II. Several recently developed CDK7 inhibitors (CDK7i) have been shown to be non-toxic and to limit tumour growth for a number of cancer cell types and are now in Phase I/II clinical trials. However, the mechanisms underlying the sensitivity of particular cancer cells to CDK7 inhibition remain largely unknown. To improve the outcome of individual patients and increase the chances of successful CDK7i approval, we assessed which fundamental cellular processes determine sensitivity to CDK7 inhibition, using the highly specific CDK7 inhibitor ICEC0942. Our data shows that selective CDK7 inhibition acutely arrests cells in the G1 phase of the cell cycle, which over time leads to senescence. Through a genome-wide CRISPR knock-out chemogenetic screen we identified active mTOR (mammalian target of rapamycin) signalling, as an important determinant of ICEC0942-induced senescence and show that a cancer-associated mutation that promotes cell growth can increase sensitivity to ICEC0942. Our work indicates that cellular growth is an important predictive marker for sensitivity to CDK7i.


  • Open Access

    Viral protein engagement of GBF1 induces host cell vulnerability through synthetic lethality

    by Arti T Navare, Fred D Mast, Jean Paul Olivier, Thierry D Bertomeu, Maxwell Neal, Lindsay N Carpp, Alexis Kaushansky, Jasmin Coulombe-Huntington, Mike Tyers, John D Aitchison

    Viruses co-opt host proteins to carry out their lifecycle. Repurposed host proteins may thus become functionally compromised; a situation analogous to a loss-of-function mutation. We term such host proteins viral-induced hypomorphs. Cells bearing cancer driver loss-of-function mutations have successfully been targeted with drugs perturbing proteins encoded by the synthetic lethal partners of cancer-specific mutations. Synthetic lethal interactions of viral-induced hypomorphs have the potential to be similarly targeted for the development of host-based antiviral therapeutics. Here, we use GBF1, which supports the infection of many RNA viruses, as a proof-of-concept. GBF1 becomes a hypomorph upon interaction with the poliovirus protein 3A. Screening for synthetic lethal partners of GBF1 revealed ARF1 as the top hit, disruption of which, selectively killed cells that synthesize poliovirus 3A. Thus, viral protein interactions can induce hypomorphs that render host cells vulnerable to perturbations that leave uninfected cells intact. Exploiting viral-induced vulnerabilities could lead to broad-spectrum antivirals for many viruses, including SARS-CoV-2. Summary: Using a viral-induced hypomorph of GBF1, Navare et al., demonstrate that the principle of synthetic lethality is a mechanism to selectively kill virus-infected cells.


  • Open Access

    Imipridone Anticancer Compounds Ectopically Activate the ClpP Protease and Represent a New Scaffold for Antibiotic Development

    by Samuel Jacques, Almer M. van der Sloot, Caroline C. Huard, Jasmin Coulombe-Huntington, Sarah Tsao, Sylvain Tollis, Thierry Bertomeu, Elizabeth J. Culp, Daniel Pallant, Michael A Cook, et al.

    Systematic genetic interaction profiles can reveal the mechanisms-of-action of bioactive compounds. The imipridone ONC201, which is currently in cancer clinical trials, has been ascribed a variety of different targets. To investigate the genetic dependencies of imipridone action, we screened a genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) knockout library in the presence of either ONC201 or its more potent analog ONC212. Loss of the mitochondrial matrix protease CLPP or the mitochondrial intermediate peptidase MIPEP conferred strong resistance to both compounds. Biochemical and surrogate genetic assays showed that impridones directly activate CLPP and that MIPEP is necessary for proteolytic maturation of CLPP into a catalytically competent form. Quantitative proteomic analysis of cells treated with ONC212 revealed degradation of many mitochondrial as well as nonmitochondrial proteins. Prompted by the conservation of ClpP from bacteria to humans, we found that the imipridones also activate ClpP from Escherichia coli, Bacillus subtilis, and Staphylococcus aureus in biochemical and genetic assays. ONC212 and acyldepsipeptide-4 (ADEP4), a known activator of bacterial ClpP, caused similar proteome-wide degradation profiles in S. aureus. ONC212 suppressed the proliferation of a number of Gram-positive (S. aureus, B. subtilis, and Enterococcus faecium) and Gram-negative species (E. coli and Neisseria gonorrhoeae). Moreover, ONC212 enhanced the ability of rifampin to eradicate antibiotic-tolerant S. aureus persister cells. These results reveal the genetic dependencies of imipridone action in human cells and identify the imipridone scaffold as a new entry point for antibiotic development.